Biogen and Invitae Announce Availability of Rapid Results in Genetic Testing Program for Spinal Muscular Atrophy (SMA) to Improve Speed of Diagnosis for PatientsGlobeNewsWire • 08/20/19
Invitae Corporation (NVTA) CEO Sean George on Q2 2019 Results - Earnings Call TranscriptSeeking Alpha • 08/07/19
InVitae Analyst: Acquisition Beefs Up Company's Hereditary Cancer Testing CapacityBenzinga • 07/12/19
Invitae Corporation (NVTA) CEO Sean George on Q1 2019 Results - Earnings Call TranscriptSeeking Alpha • 05/08/19